BioSpace News Archive

Bristol Myers Squibb to Present at J.P. Morgan’s 40th Annual Healthcare Conference.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment in THRIVE-AA2, the second Phase 3 clinical trial to evaluate the efficacy and safety of CTP‑543, an oral Janus kinase (JAK) inhibitor, in adult patients with moderate to severe alopecia areata.

ANANDA Scientific Inc today announced approval by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder.

Enanta Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference.

Seres Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 23,000 shares of KalVista common stock on January 3, 2022 as inducements material to each employee entering into employment with KalVista.

Anebulo Pharmaceuticals, Inc. has named Simon Allen as Chief Executive Officer and a member of the company’s Board of Directors, effective February 1st , 2022.

Apollomics Inc. today announced that Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer of Apollomics, was recently appointed to Chairman of the Board for the BayHelix Group, effective January 2022.

Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Biogen exercised its option to obtain from Ionis a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB115/ION306.

Stealth BioTherapeutics Corp announced that Reenie McCarthy, CEO, will present at the H.C. Wainwright BioConnect Virtual Conference taking place from January 10-13, 2022.